Results 121 to 130 of about 74,509 (297)

Advancing pharmacometrics in Africa—Transition from capacity development toward job creation

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 407-419, March 2025.
Abstract Trained pharmacometricians remain scarce in Africa due to limited training opportunities, lack of a pharmaceutical product development ecosystem, and emigration to high‐income countries. The Applied Pharmacometrics Training (APT) fellowship program was established to address these gaps and specifically foster job creation for talent retention.
Goonaseelan (Colin) Pillai, Samer Mouksassi, Innocent G. Asiimwe, Craig R. Rayner, Steven Kern, Phumla Sinxadi, Paolo Denti, Eric Decloedt, Catriona Waitt, Bernhards R. Ogutu, Rik de Greef   +10 more
wiley   +1 more source

Clinical trials in pharmacogenetics and pharmacogenomics: Methods and applications [PDF]

, 2000
Patrice Rioux
openalex   +1 more source

Predicting Systemic and Liver Bosentan Exposure Using Physiologically‐Based Pharmacokinetic Modeling

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Bosentan is the first approved oral medication for pulmonary arterial hypertension, yet the black‐box warning on its labeling implies a substantial risk of liver injury associated with bosentan exposure. The risk assessment of bosentan‐induced liver injury requires a thorough understanding of the underlying mechanisms, for which there is ...
Miao‐Chan Huang, Julia Macente, Sofie Heylen, Chen Ning, Kristof De Vos, Neel Deferm, Pieter Annaert   +6 more
wiley   +1 more source

CCS‐Consensuser: A Haplotype‐Aware Consensus Generator for PacBio Amplicon Sequences

Molecular Ecology Resources, EarlyView.
ABSTRACT DNA sequencing technology has undergone substantial improvements in recent years, to the extent that Third Generation Sequencing platforms are capable of massively generating long‐reads. Amplicon sequencing has been among the most popular techniques due to its wide application in diverse fields of biological sciences.
Carlos Congrains, Forest Bremer, Julian R. Dupuis, Norman B. Barr, Ivonne J. Garzón‐Orduña, Daniel Rubinoff, Camiel Doorenweerd, Michael San Jose, Kimberley Morris, Angela Kauwe, Scott Geib   +10 more
wiley   +1 more source

Update on the pharmacogenomics of pain management

Pharmacogenomics and Personalized Medicine, 2019
Alan David Kaye,1 Andrew Jesse Garcia,2 O Morgan Hall,3 George M Jeha,4 Kelsey D Cramer,4 Amanda L Granier,4 Anusha Kallurkar,5 Elyse M Cornett,5 Richard D Urman61Department of Anesthesiology, LSU Health Sciences Center, New Orleans, LA, USA; 2Department
Kaye AD, Garcia AJ, Hall OM, Jeha GM, Cramer KD, Granier AL, Kallurkar A, Cornett EM, Urman RD   +8 more
doaj  

The challenge of pharmacogenetics and pharmacogenomics [PDF]

, 2000
Robert Snedden
openalex   +1 more source

Evaluation of commonly used ectoderm markers in iPSC trilineage differentiation. [PDF]

, 2019
Patient-derived induced pluripotent stem cells (iPSCs) have become a promising resource for exploring genetics of complex diseases, discovering new drugs, and advancing regenerative medicine.
Iacovino, Michelina, Iribarren, Carlos, Krauss, Ronald M, Kuang, Yu-Lin, Mattis, Aras N, Medina, Marisa W, Munoz, Antonio, Nalula, Gilbert, Sanchez, Gabriela, Sanghez, Valentina, Santostefano, Katherine E, Terada, Naohiro   +11 more
core  

Pharmacogenomics in Practice [PDF]

Clinical Pharmacology & Therapeutics, 2019
Liewei Wang, Richard M. Weinshilboum
openaire   +3 more sources

Incentivizing the Utilization of Pharmacogenomics in Drug Development [PDF]

, 2012
Pharmacogenomics, the study and development of compounds according to how an individual’s genes affects the body’s response to drugs, holds enormous promise for increasing the safety and efficiency of drug development while decreasing adverse reactions ...
Koch, Valerie Gutmann
core   +1 more source

Complementary Predictors for Asthma Attack Prediction in Children: Salivary Microbiome, Serum Inflammatory Mediators, and Past Attack History

Allergy, EarlyView.
In this two‐phase study, school‐aged children were classified as at risk or no‐risk based on severe attacks during one‐year follow‐up. Four types of prediction models were developed. Salivary bacteria and serum inflammatory markers, while informative alone, complement past asthma attacks in predicting future attack risk.
Shahriyar Shahbazi Khamas, Paul Brinkman, Anne H. Neerincx, Susanne J. H. Vijverberg, Simone Hashimoto, Jelle M. Blankestijn, Jan Willem Duitman, Tamara Dekker, Barbara S. Smids, Suzanne W. J. Terheggen‐Lagro, René Lutter, Nariman K. A. Metwally, Fleur Sondaal, Eric G. Haarman, Peter J. Sterk, Ian M. Adcock, Charles Auffray, Corinna Bang, Aruna T. Bansal, Heike Buntrock‐Döpke, Klaus Bønnelykke, Andrew Bush, Bo Lund Chawes, Kian Fan Chung, Paula Corcuera‐Elosegui, Sven‐Erik Dahlén, Ratko Djukanovic, Louise J. Fleming, Stephen J. Fowler, Andre Franke, Urs Frey, Mario Gorenjak, Susanne Brandstetter, Susanne Harner, Gunilla Hedlin, Michael Kabesch, Nazanin Zounemat‐Kermani, Parastoo Kheirolldein, Alexander Kiefer, Jon R. Konradsen, Aletta D. Kraneveld, Leyre López‐Fernández, Clare S. Murray, Björn Nordlund, Maria Pino‐Yanes, Uroš Potočnik, Graham Roberts, Jakob Stokholm, Søren Johannes Sørensen, Olaia Sardón‐Prado, Dominick E. Shaw, Florian Singer, Ana R. Sousa, Jonathan Thorsen, Antoaneta A. Toncheva, Nadja H. Vissing, Christine Wolff, Mahmoud I. Abdel‐Aziz, Anke H. Maitland‐van der Zee, on behalf of the SysPharmPediA and U‐BIOPRED Consortia   +59 more
wiley   +1 more source